Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Account Payables: 2020-2025

Historic Change in Account Payables for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$1.8 million.

  • 4D Molecular Therapeutics' Change in Account Payables fell 261.61% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 334.60%. This contributed to the annual value of $871,000 for FY2024, which is 2.79% down from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Change in Account Payables stood at -$1.8 million, which was down 140.38% from $4.5 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Change in Account Payables high stood at $4.5 million for Q2 2025, and its period low was -$1.8 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Account Payables was -$235,000 (2025), whereas its average is $385,818.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Change in Account Payables tumbled by 313.46% in 2022 and then soared by 678.75% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Change in Account Payables (Quarterly) stood at $1.7 million in 2021, then dropped by 8.97% to $1.5 million in 2022, then plummeted by 171.91% to -$1.1 million in 2023, then surged by 234.38% to $1.5 million in 2024, then plummeted by 261.61% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, $4.5 million for Q2 2025, and -$235,000 during Q1 2025.